Areas covered: Sodium zirconium cyclosilicate (ZS-9), a novel, non-absorbed, potassium-selective cation exchanger, has demonstrated activity in acutely lowering and maintaining normal potassium levels. This action removes potassium from the body overall, thus helping to lower the potassium levels in the blood. 25 In acute symptomatic hyperkalemia, extracellular potassium can be lowered by shifting it into the intracellular compartment. External ID: D10727. 1 hour. Sodium zirconium cyclosilicate (ZS-9) is a highly selective cation exchanger that entraps potassium in the intestinal tract in exchange for sodium and hydrogen (Fig. Toggle navigation. New Window. New Window. 2 It is administered orally and is odorless, tasteless, and stable at room temperature. Serum K + ≥5.0 mEq/L was associated with an increased risk of all-cause mortality in patients with HF, diabetes, CKD, all 3, or none of these comorbidities. The real question is how effective it may be. Repeat as … Sodium zirconium cyclosilicate. Mechanism of action. Researchers reported results of the phase 3b DIALIZE study that examined sodium zirconium cyclosilicate (SZC) in the management of hyperkalemia in patients with end-stage renal disease on maintenance hemodialysis. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An … ZS-9 compound. 分子量 : 561.6068. 4.1 Pregnancy Rating; 4.2 Lactation risk; 4.3 Renal Dosing; 4.4 Hepatic Dosing; 5 Contraindications; 6 Adverse Reactions. Sodium zirconium cyclosilicate (Lokelma™) [hereafter referred to as SZC] is a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium and ammonium ions in the gastrointestinal tract (GIT), thereby increasing faecal potassium excretion and lowering serum potassium levels. Accumulating evidence over the last five years supports the drug’s safety. Use: Labeled Indications. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, lowering serum potassium levels. Your doctor may tell you to reduce the sodium in your diet. Help. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. Stir and drink immediately. 1,11 It does not expand when mixed with water, unlike sodium polystyrene sulfonate, which expands to 80% to 100% of its original volume. . Related Compounds: PubChem CID. Property Name Property Value Reference ; Molecular Weight: 371.5 g/mol: Computed by … 質量 : 559.8698. Generic Name: sodium zirconium cyclosilicate Brand Name: Lokelma Manufacturer: AstraZeneca Canada Inc. Therapeutic Area: Hyperkalemia, adults Indications: Hyperkalemia, adults Manufacturer Requested Reimbursement Criteria 1: Corrective treatment of hyperkalemia in adult patients (10 g administered three times per day, for 48 hours but up to 72 hours as needed), in line with the … CID 92042806 (Lokelma (TN)) Component CID. 2.4.2 Depositor-Supplied Synonyms. The FDA approval is supported by data from three double-blind, placebo-controlled trials and two open-label trials, which showed that for patients receiving Lokelma, the onset of action was at 1.0 h and the median time to achieving normal potassium levels in … 10g administered up to three times over 10h (at 0, 4 and 10h). Download. PMID: 32892634. Watch for signs of swelling in your body especially if you limit sodium in your diet or are likely to have fluid retention in your body due to heart or kidney problems. This study will evaluate the efficacy, safety and tolerability of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in children <18 years of age. Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. Sodium zirconium cyclosilicate (ZS‐9) is a new oral agent used in the management of hyperkalaemia. 1 Administration [1] 2 Adult Dosing. 11. Sodium zirconium cyclosilicate (SZC) is a new potassium binder recently approved for the treatment of chronic hyperkalemia. Feces . Find prescribing information for LOKELMA™ (sodium zirconium cyclosilicate) from AstraZeneca. LOKELMA contains 400 mg of sodium in each 5 g dose. If any powder remains in the cup, add more water, then stir and drink. 3. 3H4SiO4. Commercial arrangement. Sodium zirconium cyclosilicate is an insoluble, non-absorbed, non-polymer inorganic material designed to bind potassium ions with proven selectivity to treat hyperkalaemia. 1. Dosage and Administration. LOKELMA is a odorless, insoluble white to grey powder for oral suspension. PubChem. None. MeSH. Epub 2020 Sep 7 doi: 10.1080/14656566.2020.1810234. Sodium zirconium cyclosilicate (USAN); Sodium zirconium cyclosilicate hydrate (JAN) 商品名 : ロケルマ (アストラゼネカ) 商品一覧 . If you are in the US and would like additional information regarding AstraZeneca drugs, please contact the Information Center at AstraZeneca at 800-236-9933 800-236-9933. It has a mean particle size of 20 µm and includes no more than 3% of particles with a diameter below 3 µm. ZS‐9, a selective potassium binder, is the first in its drug class. Onset of Action. 3 Chemical and Physical Properties. Marketed ProductsLokelma (Sodium zirconium cyclosilicate): AstraZenecaLokelma is a highly-selective, oral potassium-removing agent. UZSi 9. 米国の商品 : LOKELMA (AstraZeneca Pharmaceuticals LP) 組成式 : ZrH4O6. ZS-9 compound. 2020;95(2):339-354. If you are not on dialysis, your doctor may also tell you to increase the dose of your diuretic. Revision History. As a non-absorbed, non-polymer compound, SZC lowers serum potassium levels by binding potassium in the gastrointestinal (GI) tract and promoting faecal potassium excretion. Cross-sections of ZS-9 pores with three different ions (K⁺ = potassium, Na⁺ = sodium, Ca²⁺ =... History. Learn about side effects, dosage, and more. Etiology. For maintenance treatment, … Excretion. Mayo Clin Proc. Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. Sodium zirconium cyclosilicate is a non-absorbed zirconium silicate that preferentially exchanges potassium for hydrogen and sodium. It also explained that sodium zirconium cyclosilicate would be prescribed in secondary care, that is, in hospitals. Your doctor may tell you to reduce the sodium in your diet. The primary end point was the proportion of patients during the 4-week stable dose evaluation period who … Sodium zirconium cyclosilicate (USAN) Cite. Medical. Drug: Sodium Zirconium Cyclosilicate(ZS) Suspension administered orally for a treatment period of 24h. LOKELMA ® (sodium zirconium cyclosilicate) is not indicated to reduce the risk of death. Pharmacology. Recommended starting dose is 10 g administered three times a day for up to 48 hours. Lokelma is a highly-selective, oral potassium-removing agent. Patients were randomized to receive SZC (n=97) or placebo (n=99). Sodium zirconium cyclosilicate is used to treat high blood potassium. 3.1 Computed Properties. Palmer BF. It’s not particularly new, as the original studies were performed around 2015. Source Category: Curation Efforts. The FDA approval is supported by … Sodium Zirconium Cyclosilicate (SZC) is a potassium-exchange resin similar in concept to sodium polystyrene sulfonate (Kayexalate). Sodium zirconium cyclosilicate Medical use. Contents. The active substance in Lokelma, sodium zirconium cyclosilicate, is a potassium binder. Watch for signs of swelling in your body especially if you limit sodium in your diet or are likely to have fluid retention in your body due to heart or kidney problems. 2. 2Na. Single dose contains 2 sachets of ZS 5g. Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults. 10. 1 4 Administer sodium zirconium cyclosilicate ≥2 hours before or ≥2 hours after other oral drugs unless it is determined that the other drug does not exhibit pH-dependent solubility. There is a simple discount patient access scheme for sodium zirconium cyclosilicate. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia. ZS 9. (Monday to Friday, 8 AM to 8 PM ET, excluding holidays. 1 This is a potentially serious condition caused by raised potassium levels in the blood and is frequently associated with chronic kidney disease, heart failure and diabetes. 6.1 Serious; 6.2 Common; 7 Pharmacology; 8 Mechanism of Action; 9 Comments; 10 See Also; 11 References; Administration. Lokelma (Sodium zirconium cyclosilicate): AstraZeneca . Sodium zirconium cyclosilicate (SZC) [Lokelma™] is a useful oral option for the treatment of hyperkalaemia in adults. Core Evid. Sodium zirconium cyclosilicate causes transient increases in gastric pH and can affect solubility (and consequent bioavailability) of certain pH-dependent drugs. Not systemically absorbed. Research and Development. sodium zirconium cyclosilicate. Potassium binders for hyperkalemia in chronic kidney disease–diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. 2H2O. The FDA has approved sodium zirconium cyclosilicate -- a medication that rapidly restores normal potassium levels -- for adults with hyperkalemia. Help. New Window. Sodium zirconium cyclosilicate is a potassium binder that preferentially exchanges potassium for hydrogen and sodium. Sodium zirconium cyclosilicate; Recent clinical studies. Lokelma should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. 2017;12:11-24. Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults. Help. Version: 4. Sodium zirconium cyclosilicate is a nonabsorbed, potassium-binding, inorganic cation exchange crystalline compound formulated as an insoluble, odorless, and tasteless white powder. LOKELMA contains 400 mg of sodium in each 5 g dose. When used chronically, maintenance of normal serum potassium has been demonstrated for up to 1 month. Lokelma (sodium zirconium cyclosilicate) is a prescription drug that treats hyperkalemia in adults. Metabolism. 17141-74-1. Absorption. Each 5 g of sodium zirconium cyclosilicate contains 400 mg of sodium. PubChem SID: 254741688: Structure: Source: KEGG. It explained that sodium zirconium cyclosilicate would complement rather than replace a low-potassium diet and may allow such a diet to be less strict (see section 3.5). Is this guidance up to date? CID 962 (Water) CID 14942 (Orthosilicic acid) CID 23995 (Zirconium) CID 5360545 (Sodium … Efficacy data for short-term improvement in potassium. More recently sodium zirconium cyclosilicate was introduced, which is a highly sensitive potassium binder that traps potassium in exchange for sodium or hydrogen ions. To mix the powder, follow these steps: Empty the packet (s) of sodium zirconium cyclosilicate powder into a cup of 3 tablespoons (45 mL) or more of water. Next review: 2022. It is ingested as an oral powder dispersed in liquid, is insoluble, and is not absorbed by the gut. Takkar C, Nassar T, Qunibi W Expert Opin Pharmacother 2021 Jan;22(1):19-28. Contact Market.AccessUK@astrazeneca.com for details. Status: Live. Sodium zirconium silicate (Na2ZrSi3O9) UZSi-9. 2.1 Hyperkalemia; 3 Pediatric Dosing; 4 Special Populations. When taken by mouth, Lokelma attaches to potassium from food and body fluids in the gut, forming a compound that is then eliminated in the stools.
Austria Salzburg 1995,
Swp Immobilien Blaufelden,
Lkw Unfall Mihla,
Torschützen Ligue 1,
Traumschiff Richtung Kolumbien,
Ulta Alien Perfume,
Die Brücke - Transit In Den Tod: Die Komplette Serie,
Ich Schweige Für Dich Katz,
Walvis Bay Beach,
Once Upon A Time Staffel 7 Robin,